{
    "clinical_study": {
        "@rank": "114203", 
        "arm_group": [
            {
                "arm_group_label": "LGG", 
                "arm_group_type": "Experimental", 
                "description": "LGG 10^10 cfu PO bid x 5 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "micro-crystalline cellulose PO bid x 5 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators will study the efficacy and side effect profile of LGG, a probiotic, in\n      pediatric patients with acute gastroenteritis."
        }, 
        "brief_title": "Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis", 
        "completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastroenteritis", 
        "condition_browse": {
            "mesh_term": [
                "Emergencies", 
                "Gastroenteritis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Multicenter randomized controlled trial of LGG in patients 3-48 months of age presenting to\n      the Emergency Department with acute gastroenteritis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 3-48 months (have not yet reached their fourth birthday); AND\n\n          2. Presence of 3 or more watery stools within 24 hours of screening; AND\n\n          3. Duration of vomiting or diarrhea less than 7 days; AND\n\n          4. Symptoms consistent with acute intestinal infectious process.\n\n        Exclusion Criteria:\n\n          1. Presence of an indwelling vascular access line; OR\n\n          2. Presence of structural heart disease excluding non-pathological heart murmurs; OR\n\n          3. Receiving immunosuppressive therapy or history of immunodeficiency; OR\n\n          4. Hematochezia in the preceding 48 hours; OR\n\n          5. Chronic gastrointestinal problems (e.g. short gut syndrome, inflammatory bowel\n             disease); OR\n\n          6. Patients with known pancreatitis; OR\n\n          7. Critically ill patients; OR\n\n          8. Family member with an indwelling vascular access line, or on immunosuppressive\n             therapy, or with a known immunodeficiency; OR\n\n          9. Bilious emesis; OR\n\n         10. Probiotic use (supplement) in the preceding 2 weeks; OR\n\n         11. Allergy to lactobacillus or Microcrystalline Cellulose (MCC); OR\n\n         12. Allergy to erythromycin, clindamycin, AND Beta-lactam antibiotics (all); OR\n\n         13. Patients who have already been enrolled in the study once; OR\n\n         14. Not available for daily follow-up while symptomatic; OR\n\n         15. Parent/guardian not speaking English or Spanish."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "48 Months", 
            "minimum_age": "3 Months"
        }, 
        "enrollment": {
            "#text": "900", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773967", 
            "org_study_id": "1 R01 HD071915-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "LGG", 
                "description": "LGG 10^10 cfu PO BID X 5 days", 
                "intervention_name": "LGG", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Lactobacillus GG ATCC 53103", 
                    "Lactobacillus rhamnosus", 
                    "culturelle"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "1 capsule PO bid x 5 days", 
                "intervention_name": "micro-crystalline cellulose", 
                "intervention_type": "Drug", 
                "other_name": "placebo micro-crystalline cellulose"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Lactobacillus rhamnosus GG", 
            "LGG", 
            "Probiotic", 
            "Gastroenteritis", 
            "acute gastroenteritis", 
            "child", 
            "pediatric", 
            "RCT"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "number_of_arms": "2", 
        "official_title": "Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis", 
        "overall_contact": {
            "email": "schnadower_d@kids.wustl.edu", 
            "last_name": "David Schnadower, MD", 
            "phone": "314 747 5604"
        }, 
        "overall_contact_backup": {
            "email": "Tarr@kids.wustl.edu", 
            "last_name": "Phillip I Tarr, MD", 
            "phone": "314 286 2848"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "David Schnadower, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "This is a validated gastroenteritis severity score that includes duration and frequency of diarrhea, duration and frequency of vomiting, duration and frequency of fever and use of health care resources", 
                "measure": "Modified Vesikari Score", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "presence of severe adverse events up to 1 year after treatment", 
                "measure": "Severe adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773967"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Washington University School of Medicine", 
            "investigator_full_name": "David Schnadower", 
            "investigator_title": "Assistant Professor of Pediatrics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Columbia University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Northwestern University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Children's Research Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Utah", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Wayne State University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Children's Hospital Medical Center, Cincinnati", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Michigan", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Brown University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of California, Davis", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}